Picture of Taiko Pharmaceutical Co logo

4574 Taiko Pharmaceutical Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m+1.01%
3m-2.6%
6m-20.21%
1yr-14.45%
Volume Change (%)
10d/3m+29.36%
Price vs... (%)
52w High-44.24%
50d MA-1.51%
200d MA-22.17%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)48.57
PEG Ratio (f)n/a
EPS Growth (f)-62.84%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value1.74
Price to Tang. Book1.75
Price to Free Cashflow79.16
Price to Sales2.2
EV to EBITDA15.09

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital4.93%
Return on Equity12.22%
Operating Margin7.88%

Financial Summary

Year End 31st DecUnit202020212022202320242025E2026ECAGR / Avg
Total Revenue¥m14,966.1711,2995,0406,1206,2927,3007,700-9.59%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+89.89n/an/an/an/a-69.41-16.67n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Taiko Pharmaceutical Co EPS forecast chart

Profile Summary

TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.

Directors

Last Annual
December 31st, 2024
Last Interim
December 31st, 2024
Incorporated
November 18th, 1946
Public Since
March 18th, 2009
No. of Shareholders
14,889
No. of Employees
214
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
50,193,711

4574 Share Price Performance

Upcoming Events for 4574

Q1 2025 Taiko Pharmaceutical Co Ltd Earnings Release

Similar to 4574

Picture of Astellas Pharma logo

Astellas Pharma

jp flag iconTokyo Stock Exchange

Picture of Astena Holdings Co logo

Astena Holdings Co

jp flag iconTokyo Stock Exchange

Picture of CanBas Co logo

CanBas Co

jp flag iconTokyo Stock Exchange

Picture of CellSeed logo

CellSeed

jp flag iconTokyo Stock Exchange

FAQ